Refine
Year of publication
Document Type
- Article (46)
- Conference Proceeding (10)
Has Fulltext
- yes (56)
Is part of the Bibliography
- no (56) (remove)
Keywords
- Hemorrhage (4)
- meningioma (3)
- Death rates (2)
- Lesions (2)
- Multivariate analysis (2)
- Neurology (2)
- Prognosis (2)
- Pulmonary embolism (2)
- Quality of life (2)
- Subarachnoid hemorrhage (2)
- dexamethasone (2)
- dysphagia (2)
- glioblastoma (2)
- glioma (2)
- AVM hemorrhage (1)
- Acute-on-chronic subdural hematoma (1)
- Aneurysm (1)
- Aneurysms (1)
- Angiography (1)
- Anticoagulant therapy (1)
- Antiplatelet therapy (1)
- Apoptosis (1)
- Blood (1)
- Blood groups (1)
- Brain metastasis (1)
- Brain tumor surgery (1)
- Breast cancer (1)
- CMS (1)
- COVID-19 (1)
- Cancer treatment (1)
- Cerebral vasospasm (1)
- Computational model (1)
- Conservative treatment (1)
- Coronary heart disease (1)
- DBS (1)
- DNA damage (1)
- Deep brain stimulation (1)
- Diagnostic medicine (1)
- Direct oral anticoagulation (1)
- Ellipsoids (1)
- Epidural abscess (1)
- Epidural block (1)
- Epileptic seizures (1)
- Frontobasal (1)
- Glioblastoma (1)
- Glioblastoma survival (1)
- Glioma (1)
- HOD (1)
- Hardware erosion (1)
- Health care (1)
- Hedgehog (1)
- Hydrocephalus (1)
- Impulse generator (1)
- Infarction (1)
- KOOS IV (1)
- KPS (1)
- Left hemisphere (1)
- Linear regression analysis (1)
- Low-molecular-weight heparin (1)
- Magnetic resonance imaging (1)
- Malignant meningioma (1)
- Medical ethics (1)
- Medical research (1)
- Medical risk factors (1)
- Meningioma (1)
- Molecular signatures (1)
- Morbidity (1)
- Necrosis (1)
- Network model (1)
- Neuroimaging (1)
- Neuropilin (1)
- Non-aneurysmal (1)
- Non-perimesencephalic (1)
- Non-small cell lung cancer (1)
- Notch (1)
- Numerical simulation (1)
- Olfactory groove meningioma (1)
- Oncology (1)
- Outcome (1)
- Outcomes research (1)
- PEI (1)
- Parkinson’s disease (1)
- Perimesencephalic (1)
- Peritumoural oedema (1)
- Precision oncology (1)
- Prepontine (1)
- Prognostic biomarker (1)
- Pyogenic spondylodiscitis (1)
- Regression analysis (1)
- Resection (1)
- Return to work (1)
- Risk factor (1)
- SAH (1)
- SAH close (1)
- SF-36 (1)
- SKALE score (1)
- STAMPE2 (1)
- STAT3 (1)
- Scalp defect (1)
- Seizure (1)
- Signs and symptoms (1)
- Skull base (1)
- Status epilepticus (1)
- Stereotactic radiosurgery (1)
- Surgery (1)
- Systems biology (1)
- Systems medicine (1)
- TTFields (1)
- Therapeutic anticoagulation (1)
- Tissue expander (1)
- Toxicity (1)
- VEGF (1)
- VEGF receptors (1)
- VIM (1)
- Volumetric analysis (1)
- anaemia (1)
- aneurysm (1)
- anticonvulsants (1)
- aspiration (1)
- blood culture (1)
- brain cancer (1)
- brain infection (1)
- brain shift (1)
- brain tumor (1)
- cancer stem cells (1)
- carpal tunnel syndrome (1)
- cerebellar mutism (1)
- cerebellum (1)
- cerebral imaging (1)
- cerebral vasospasm (CVS) (1)
- clinical outcome (1)
- corticosteroids (1)
- delayed cerebral ischemia (DCI) (1)
- elderly (1)
- epilepsy (1)
- essential tremor (1)
- facial nerve functional outcome (1)
- functional outcome (1)
- glioma microenvironment (1)
- healthcare system (1)
- hearing nerve (1)
- immune infiltration (1)
- lipopolyplex (1)
- long-term outcome (1)
- medulloblastoma (1)
- microsurgical treatment (1)
- neurosurgery (1)
- neurysmal subarachnoid hemorrhage (aSAH) (1)
- non-aneurysmal (1)
- non-aneurysmal SAH (1)
- non-perimesencephalic (1)
- pandemic (1)
- perimesencephalic (1)
- peripheral nerve (1)
- peritumoral edema (1)
- peritumoral edema zone (1)
- polyethylenimine (1)
- posterior fossa tumor (1)
- predictor (1)
- prepontine (1)
- recovery (1)
- red blood cells (1)
- regenerative medicine (1)
- revision surgery (1)
- seizures (1)
- short-term (1)
- siRNA delivery (1)
- siRNA/RNAi (1)
- speech and language pathologist (1)
- spinal infection (1)
- statin treatment (1)
- stroke (1)
- subarachnoid hemorrhage (1)
- subdural hematoma (1)
- surgery (1)
- survival (1)
- swallowing (1)
- transfusion (1)
- translational investigation (1)
- translational study (1)
- ventralis intermedius nucleus (1)
- vestibular schwannoma (1)
Institute
- Medizin (56) (remove)
Background: Dexamethasone (Dex) is the most common corticosteroid to treat edema in glioblastoma (GBM) patients. Recent studies identified the addition of Dex to radiation therapy (RT) to be associated with poor survival. Independently, Tumor Treating Fields (TTFields) provides a novel anti-cancer modality for patients with primary and recurrent GBM. Whether Dex influences the efficacy of TTFields, however, remains elusive.
Methods: Human GBM cell lines MZ54 and U251 were treated with RT or TTFields in combination with Dex and the effects on cell counts and cell death were determined via flow cytometry. We further performed a retrospective analysis of GBM patients with TTFields treatment +/- concomitant Dex and analysed its impact on progression-free (PFS) and overall survival (OS).
Results: The addition of Dex significantly reduced the efficacy of RT in U251 and MZ54 cells. TTFields (200 kHz/250 kHz) induced massive cell death in both cell lines. Concomitant treatment of TTFields and Dex did not reduce the overall efficacy of TTFields. Further, in our retrospective clinical analysis, we found that the addition of Dex to TTFields therapy did not influence PFS nor OS.
Conclusion: Our translational investigation indicates that the efficacy of TTFields therapy in patients with GBM and primary GBM cell lines is not affected by the addition of Dex.
Purpose: Dexamethasone (Dex) is the most common corticosteroid to treat edema in glioblastoma (GBM) patients. Recent studies identified the addition of Dex to radiation therapy (RT) to be associated with poor survival. Independently, Tumor Treating Fields (TTFields) provides a novel anti-cancer modality for patients with primary and recurrent GBM. Whether Dex influences the efficacy of TTFields, however, remains elusive. Methods: Human GBM cell lines MZ54 and U251 were treated with RT or TTFields in combination with Dex and the effects on cell counts and cell death were determined via flow cytometry. We further performed a retrospective analysis of GBM patients with TTFields treatment +/- concomitant Dex and analysed its impact on progression-free (PFS) and overall survival (OS). Results: The addition of Dex significantly reduced the efficacy of RT in U251, but not in MZ54 cells. TTFields (200 kHz/250 kHz) induced massive cell death in both cell lines. Concomitant treatment of TTFields and Dex did not reduce the overall efficacy of TTFields. Further, in our retrospective clinical analysis, we found that the addition of Dex to TTFields therapy did not influence PFS nor OS. Conclusion: Our translational investigation indicates that the efficacy of TTFields therapy in patients with GBM and GBM cell lines is not affected by the addition of Dex.
Glioblastoma (GBM) is a cancer type with high thrombogenic potential and GBM patients are therefore at a particularly high risk for thrombotic events. To date, only limited data on anticoagulation management after pulmonary embolism (PE) in GBM is available and the sporadic use of DOACs remains off-label. A retrospective cohort analysis of patients with GBM and postoperative, thoracic CT scan confirmed PE was performed. Clinical course, follow-up at 6 and 12 months and the overall survival (OS) were evaluated using medical charts and neuroradiological data. Out of 584 GBM patients, 8% suffered from postoperative PE. Out of these, 30% received direct oral anticoagulants (DOACs) and 70% low-molecular-weight heparin (LMWH) for therapeutic anticoagulation. There was no significant difference in major intracranial hemorrhage (ICH), re-thrombosis, or re-embolism between the two cohorts. Although statistically non-significant, a tendency to reduced mRS at 6 and 12 months was observed in the LMWH cohort. Furthermore, patients receiving DOACs had a statistical benefit in OS. In our analysis, DOACs showed a satisfactory safety profile in terms of major ICH, re-thrombosis, and re-embolism compared to LMWH in GBM patients with postoperative PE. Prospective, randomized trials are urgent to evaluate DOACs for therapeutic anticoagulation in GBM patients with PE.
Due to anticipated postoperative neuropsychological sequelae, patients with gliomas infiltrating the corpus callosum rarely undergo tumor resection and mostly present in a poor neurological state. We aimed at investigating the benefit of glioma resection in the corpus callosum, hypothesizing neuropsychological deficits were mainly caused by tumor presence. Between 01/2017 and 1/2020, 21 patients who underwent glioma resection in the corpus callosum were prospectively enrolled into this study. Neuropsychological function was assessed preoperatively, before discharge and after 6 months. Gross total tumor resection was possible in 15 patients, and in 6 patients subtotal tumor resection with a tumor reduction of 97.7% could be achieved. During a median observation time of 12.6 months 9 patients died from glioblastoma after a median of 17 months. Preoperatively, all cognitive domains were affected in up to two thirds of patients, who presented a median KPS of 100% (range 60–100%). After surgery, the proportion of impaired patients increased in all neurocognitive domains. Most interestingly, after 6 months, significantly fewer patients showed impairments in attention, executive functioning, memory and depression, which are domains considered crucial for everyday functionality. Thus, the results of our study strongly support our hypothesis that in patients with gliomas infiltrating the corpus callosum the benefit of tumor resection might outweigh morbidity.
Background: Glioblastoma (GBM) is a cancer type with high thrombogenic potential and GBM patients are therefore at a particularly high risk for thrombotic events. To date only limited data on anticoagulation management after pulmonary embolism (PE) in GBM is available and the sporadic use of DOACs remains off-label.
Methods: A retrospective cohort analysis of patients with GBM and postoperative, thoracic CT-scan confirmed, PE was performed. Clinical course, follow-up at 6 and 12 months and the overall survival (OS) were evaluated using medical charts and neuroradiological data.
Results: Out of 584 GBM patients, 8% suffered from postoperative PE. Out of theses, 30% received direct oral anticoagulants (DOACs) and 70% low-molecular-weight heparin (LMWH) for therapeutic anticoagulation. There was no significant difference in major intracranial hemorrhage (ICH), re-thrombosis or re-embolism between the two cohorts. Although statistically non-significant, a tendency to reduced mRS at 6- and 12 months was observed in the LMWH cohort. Furthermore, patients receiving DOACs had a statistical benefit in OS.
Conclusion: In our analysis DOACs showed a satisfactory safety profile in terms of major ICH, re-thrombosis and re-embolism compared to LMWH in GBM patients with postoperative PE. Prospective, randomized trials are urgent to evaluate DOACs for therapeutic anticoagulation in GBM patients with PE.
Background: Previous studies reported decreased volumes of acute stroke admissions during the COVID-19 pandemic. We aimed to examine whether aneurysmal subarachnoid hemorrhage (aSAH) volumes demonstrated similar declines in our department. Furthermore, the impact of the pandemic on disease progression should be analyzed.
Methods: We conducted a retrospective study in the neurosurgical department of the university hospital Frankfurt including patients with the diagnosis of aSAH during the first year of the COVID pandemic. One year cumulative volume for aSAH hospitalization procedures was compared to the year before (03/2020 – 02/2021 vs. 03/2019 – 02/2020) and the last 5 pre-COVID-pandemic years (2015-2020). All relevant patient characteristics concerning family history, disease history, clinical condition at admission, active/past COVID-infection, treatment management, complications, and outcome were analyzed.
Results: Compared to the 84 hospital admissions during the pre-pandemic years, the number of aSAH hospitalizations (n = 56) declined during the pandemic without reaching significance. No significant difference in the analyzed patient characteristics including clinical condition at onset, treatment, complications, and outcome, between 56 patients with aSAH admitted during the COVID pandemic and the treated patients in the last 5 years in the pre-COVID period were found. In our multivariable analysis, we detected young age (p < 0.05; OR 4.2) and no existence of early hydrocephalus (p < 0.05; OR 0.13) as important factors for a favorable outcome (mRS ≤ 0–2) after aSAH during the COVID pandemic. A past COVID-infection was detected in young patients suffering from aSAH (Age < 50years, p < 0.05; OR 10.5) with an increased rate of cerebral vasospasm after aSAH onset (p < 0.05; OR 26). Nevertheless, past COVID-infection did not reach significance as a high-risk factor for unfavorable outcomes.
Conclusion: There was a relative decrease in the number of patients with aSAH during the COVID-19 pandemic. Despite the extremely different conditions of hospitalization, there was no impairing significant effect on the treatment and outcome of admitted patients with aSAH. A past COVID infection seemed to be an irrelevant limiting factor concerning favorable outcomes.